Some information, however, can be gleaned from the results reported in our study. First, the median (interquartile range [IQR] ) serum testosterone level in our treated cohort during follow-up was 318 (237-435) ng/dL compared with the untreated population with a median (IQR) 212 (160-253) ng/dL; testosterone replacement therapy resulted in a significant increase in serum levels with over half of the patients normalizing their serum testosterone levels. Second, although we did not generate a Framingham Risk Score for the patients in our study, 1 we did conduct a stratified analysis restricted to men with baseline cardiovascular risk factors and the results from this stratified analysis were consistent with our overall study findings. Third, we have seen the beneficial effects of treating hypertension or hyperlipidemia in our population in recent years, 3 suggesting that this could affect our results. Thus, we included calendar year in our adjusted models and found a lower risk of cardiovascular outcomes over time potentially related to changing treatment patterns and/or length of follow-up. We believe the questions posed by Stavropoulos and colleagues probe important nuances about the potential relationship between testosterone replacement therapy and cardiovascular disease outcomes. Undoubtedly, further focused studies based in other cohorts of men, from different settings, could provide important new insights.
T. Craig Cheetham, PharmD, MS Stephen K. VanDenEeden, PhD Steven J. Jacobsen, MD, PhD we would like to mention that the beneficial effect of correcting unexplained anemia through testosterone supplementation might be attributable to down-regulation of serum hepcidin, the master regulator of iron homeostasis. Previous studies have revealed that elderly with an unexplained anemia have elevated levels of serum hepcidin. 4 Because testosterone is known to be a prominent suppressor of serum hepcidin, 5 it is likely that serum hepcidin will decrease, and subsequently, iron availability will improve and lead to a more effective erythropoiesis. Future studies evaluating the effect of testosterone supplementation on hemoglobin levels might want to consider measuring serum hepcidin as putative mechanism. 3 ferritin levels 45 to 75 ng/mL were suspected to be related to iron deficiency only on the basis of blood film evaluation, not the demonstration of absent iron stores, as was the case for those with levels less than 45 ng/mL. Even some patients whose levels were less than 45 ng/mL had iron stores present. Thus misclassification may occur in either direction. Similarly, B12 levels have limited sensitivity and specificity, and while a value of less than 200 ng/L more likely indicates true deficiency than higher levels, some individuals whose values are greater than 200 ng/L could have relative B 12 deficiency. 4, 5 Whether this mild deficiency would be sufficient to cause anemia is uncertain. Nevertheless, while some degree of misclassification may have occurred, because testosterone treatment corrected anemias of "known" cause as well as unexplained anemia, our conclusion that testosterone improves both types of anemia in older men who have low testosterone appears solid. We emphasize that this conclusion applies only to older men with low testosterone and not to men who are anemic but have normal testosterone.
Redefining Unexplained Anemia in Elderly
With respect to the suggestion by Eisenga et al regarding the mechanism by which testosterone increased hemoglobin, we agree that testosterone may have acted by suppressing hepcidin. an important randomized clinical trial that should have a substantial influence on future clinical practice. However, it was not well designed to test the effect of intensive blood pressure control on gait speed and mobility limitation in older adults. First, according to the registration (NCT02106234), the main outcomes (gait speed and mobility limitation) of this article were not prespecified, because none of them were submitted in the registration. This limitation can lead to a selective outcome of the authors' intervention.
Intensive Blood Pressure Control on Gait
Second, the sample of older people in SPRINT 1 may not be representative of the general older population. Odden et al acknowledged that SPRINT excluded individuals with a history of diabetes or stroke, symptomatic heart failure, dementia, or an indication for specific antihypertensives. But these comorbidities have a population prevalence in elderly patients, with rates that continue to increase. 2, 3 Additionally, the only ambulatory, community-based persons were recruited into the study. 1 Therefore, the results do not generalize to many older people with multiple coexisting conditions, frailty, and disabilities. Third, it is also important to note that no information was provided about functional limitations, cognitive impairment, hearing or visual problems, and balance or postural disorders between the groups. These are generalizable to the older population, but may render the gait speed test more time-consuming than expected, representing a possible bias. 4 Fourth, the authors did not report adverse events in older patients between the intervention and control groups. In the original SPRINT, 5 serious adverse drug events occurred more frequently in the aggressively treated group, with an increase from 2.5% to 4.7% (hazard ratio, 1.88; P < .001).
Yu Zhang, MD Xiaoming Huang, MD Lvlin Chen, MD
